Replies to post #103290 on Biotech Values

[DewDiligence]

GSK, FOLD ink Fabry collaboration:

http://www.nasdaq.com/aspx/stock-market-news-story.aspx?storyid=201010290531dowjonesdjonline000315&title=glaxosmithkline-and-amicus-therapeutics-enter-amigal-pact

The up-front amount is $60M of which half is a 19.9% equity stake purchased at $4.56/sh.

[ghmm]

Modifying protein misfolding

The links may require a membership (but its free) to view.

http://www.nature.com/nrd/journal/v9/n11/pdf/nrd3316.pdf
http://www.nature.com/nrd/journal/v9/n11/full/nrd3316.html

Here is a nice article about protein misfolding. I was unaware of the Roche deal they mention and (not surprisingly) big Pharama have their own internal programs here. I think the science sounds intreging and the molecules (at least Amicus's) were extremly small and simple in structure. Hopefully this could lead to breakthroughs in many diseases especially since areas like Alzheimers could benefit from new approaches IMO.

[DewDiligence]

FDA issues RTF letter for PFE’s Tafamidis (f/k/a Fx-1006A):

http://finance.yahoo.com/news/Pfizer-Receives-Refusal-To-bw-2979025787.html?x=0&.v=1

This is the drug PFE picked up in the acquisition of FoldRx last fall (#msg-53934948). It’s probably not a needle-moving program for a company as large as PFE, but an RTF letter is still an embarrassment.